FDA adds warning label to RSV vaccines Abrysvo and Arexvy about the risk for Guillain-Barré syndrome
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
pulmonologyadvisor21h
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Medscape3d
RSV Vaccines Will Carry Warning for Guillain-Barré Syndrome
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
HealthDay on MSN11d
FDA Adds Warning Label to RSV Vaccines Abrysvo and Arexvy
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
pulmonologyadvisor3d
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome Warning
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
FDA Urges Guillain-Barré Syndrome Warning On Labels Of RSV Vaccines Abrysvo And Arexvy
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
cidrap.umn17h
Real-world study: RSV vaccine 78% to 80% effective against infection, severe illness in older US veterans
The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...
What To Expect From PFE Stock In 2025?
In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...
Renal & Urology News10d
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome Warning
According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...